Hey, when youre working with human bodies, there are a lot of variables
Weight loss slows
Managing Blood Sugar to Improve Erectile Function Optimising glycaemic control represents a fundamental strategy for preventing and potentially improving erectile dysfunction in type 2 diabetes
Similarly, Wegovy , which is specifically approved for weight loss, often comes with coverage limitations, making affordability a significant hurdle for many individuals
Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear
This article is exclusive to STAT+ subscribers Unlock this article plus daily coverage and analysis of the pharma industry by subscribing to STAT+
)
